NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

ProMIS Neurosciences, Inc. (PMN) Stock Analysis

ProMIS Neurosciences, Inc. (PMN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

PMN

$12.60

−$0.30 (−2.33%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PMN with… →

PMN Key Statistics

As of Sep 4, 2026
Trading
Open
$13.03
Previous Close
$12.90
Day's Range
12.48–13.46
52-Week Range
6.27–27.40
Volume
24.00K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.22
Valuation
Market Cap
$112.99M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−12.18
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$39.72M−1529.33%
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
8.97M
1-Year Return
+17.21%
Dividend and dates
Avg Volume
84.53K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

PMN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+84.48%
2025−71.24%
2024−17.39%
2023−73.50%
2022−34.24%
2021+37.50%
2020−38.46%
2019−35.00%
2018+17.65%
2017+70.00%
2016 (partial year)−9.09%

As of September 4, 2026.

PMN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$39.72M—
2024$0.00$2.78M—
2023$0.00−$13.21M—
2022$0.00−$18.06M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$40.17M−$39.72M—
2024$0.00—−$16.83M$2.78M—
2023$0.00—−$14.26M−$13.21M—
2022$0.00—−$23.38M−$18.06M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

PMN Valuation vs Biotechnology Median

Median of 656 stocks
MetricPMNBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

ProMIS Neurosciences, Inc. (PMN) is capitalised at $112.99M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 10.

The most recent close on file for PMN is $12.60, dated September 4, 2026. That is −$0.30 (−2.33%) against the previous close. Over the past 52 weeks the price has ranged from $6.27 to $27.40. The latest close sits 100.96% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $39.72M. Profit margin runs at 0%. Trailing earnings per share are −12.18.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The trailing one-year price return is +17.21%. Measured over 10 years, that is −23.35% a year compounded. Beta against the wider market is reported at −0.22. Annualized volatility over the trailing 10 years is 123.56%.

Growth & Income

No dividend is on file for PMN.

The strongest complete calendar year on file is 2017 at +70.00%; the weakest is 2023 at −73.50%. Of the 9 complete calendar years on file, 3 finished higher. So far in 2026 the price is +84.48%.

Peer Comparison

ProMIS Neurosciences, Inc. (PMN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
ProMIS Neurosciences, Inc. PMN $112.99M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. ProMIS Neurosciences, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About ProMIS Neurosciences, Inc.

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's disease; PMN267 for the treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for the treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.

Visit website →